K. Aogi

1.1k total citations
33 papers, 770 citations indexed

About

K. Aogi is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, K. Aogi has authored 33 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 15 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in K. Aogi's work include Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (15 papers) and HER2/EGFR in Cancer Research (13 papers). K. Aogi is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Breast Cancer Treatment Studies (15 papers) and HER2/EGFR in Cancer Research (13 papers). K. Aogi collaborates with scholars based in Japan, United States and United Kingdom. K. Aogi's co-authors include Hiroji Iwata, Norikazu Masuda, Shigemitsu Takashima, Yasuhiro Fujiwara, Yoshiaki Rai, Yosuke Sasaki, Yutaka Tokuda, Noriyuki Katsumata, Hirofumi Mukai and Steve Goodison and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

K. Aogi

33 papers receiving 761 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
K. Aogi Japan	13	535	214	185	153	131	33	770
C. Hudis United States	13	632 1.2×	204 1.0×	186 1.0×	214 1.4×	100 0.8×	59	801
Akshara Singareeka Raghavendra United States	16	519 1.0×	259 1.2×	92 0.5×	263 1.7×	320 2.4×	69	857
Sharon Wilks United States	16	688 1.3×	236 1.1×	125 0.7×	272 1.8×	405 3.1×	49	950
Alessandra Balduzzi Italy	18	710 1.3×	626 2.9×	99 0.5×	247 1.6×	169 1.3×	35	1.0k
Annalisa Volpi Italy	16	402 0.8×	300 1.4×	66 0.4×	264 1.7×	92 0.7×	34	665
Tracey Weisberg United States	7	761 1.4×	818 3.8×	202 1.1×	203 1.3×	289 2.2×	14	1.3k
Brooke Esteves United States	11	312 0.6×	201 0.9×	76 0.4×	312 2.0×	283 2.2×	31	662
Masahiro Ohara Japan	16	299 0.6×	209 1.0×	86 0.5×	193 1.3×	106 0.8×	44	654
Sam Leung Canada	8	238 0.4×	244 1.1×	47 0.3×	332 2.2×	214 1.6×	13	808
M. Piccart Belgium	13	681 1.3×	409 1.9×	55 0.3×	154 1.0×	163 1.2×	38	889

Countries citing papers authored by K. Aogi

Since Specialization

Citations

This map shows the geographic impact of K. Aogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Aogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Aogi more than expected).

Fields of papers citing papers by K. Aogi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Aogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Aogi. The network helps show where K. Aogi may publish in the future.

Co-authorship network of co-authors of K. Aogi

This figure shows the co-authorship network connecting the top 25 collaborators of K. Aogi. A scholar is included among the top collaborators of K. Aogi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Aogi. K. Aogi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tsurutani, Junji, Yukinori Ozaki, Hiroshi Ishiguro, et al.. (2024). A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Annals of Oncology. 36(1). 31–42. 9 indexed citations

Aogi, K., Kan Yonemori, Mina Takahashi, et al.. (2017). Efficacy and safety of olaparib combined with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: The final analysis of a Japanese phase I/II trial. Annals of Oncology. 28. v81–v81. 2 indexed citations

Kinoshita, Takayuki, K. Aogi, Mina Takahashi, et al.. (2017). The first report of multicenter validation study of 95-gene classifier, a multi-gene prognostic assay of estrogen receptor positive and node negative breast cancer patients. Annals of Oncology. 28. v56–v56. 1 indexed citations

Kawaguchi, Hidetoshi, Norikazu Masuda, Takahiro Nakayama, et al.. (2017). Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari). Breast Cancer Research and Treatment. 163(3). 545–554. 10 indexed citations

Niikura, Naoki, Ai Tomotaki, Hiroaki Miyata, et al.. (2015). Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry. Annals of Oncology. 27(3). 480–487. 131 indexed citations

Yamamoto, Hiroshi, Masahiko Ando, K. Aogi, et al.. (2014). Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer. Japanese Journal of Clinical Oncology. 45(1). 12–18. 21 indexed citations

Ohtani, Shoichiro, Norikazu Masuda, Y-H Im, et al.. (2013). Abstract P3-12-03: Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: First safety analysis of CREATE-X (JBCRG-04). Cancer Research. 73(24_Supplement). P3–12. 3 indexed citations

Aogi, K., Hiroji Iwata, Norikazu Masuda, et al.. (2011). A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Annals of Oncology. 23(6). 1441–1448. 105 indexed citations

Watanabe, Tomoko, Masaru Kuranami, K. Inoue, et al.. (2011). PD07-02: Docetaxel Is Superior to Paclitaxel Given Every Three Weeks in Post Operative Patients with Node-Positive Breast Cancer: Results of the Final Analyses of the NSAS-BC (National Surgical Adjuvant Study of Breast Cancer) 02 Trial from Japan.. Cancer Research. 71(24_Supplement). PD07–2. 2 indexed citations

10.

Kawaguchi, Kosuke, Hiroshi Ishiguro, Satoshi Morita, et al.. (2011). Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey. Breast Cancer Research and Treatment. 130(2). 627–634. 13 indexed citations

11.

Tamura, Kenji, Chikako Shimizu, Takashi Hojo, et al.. (2010). FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Annals of Oncology. 22(6). 1302–1307. 139 indexed citations

12.

Katsumata, Noriyuki, Toru Watanabe, Hironobu Minami, et al.. (2009). Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Annals of Oncology. 20(7). 1210–1215. 34 indexed citations

13.

Saeki, Toshiaki, Shinzaburo Noguchi, K. Aogi, et al.. (2009). Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer. Annals of Oncology. 20(5). 868–873. 4 indexed citations

14.

Toi, Masakazu, Hiroji Iwata, Yasuhiro Fujiwara, et al.. (2009). Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. British Journal of Cancer. 101(10). 1676–1682. 68 indexed citations

15.

Takabatake, Daisuke, Naruto Taira, Fumikata Hara, et al.. (2009). Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients. Japanese Journal of Clinical Oncology. 39(8). 478–483. 33 indexed citations

16.

Watanabe, Toru, Masaru Kuranami, Kenichi Inoue, et al.. (2009). Phase III trial comparing 4-cycle doxorubicin plus cyclophosphamide followed by 4-cycle taxan with 8-cycle taxan as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02 trial. Journal of Clinical Oncology. 27(15_suppl). 516–516. 4 indexed citations

17.

Watanabe, Toru, Masaru Kuranami, Kenichi Inoue, et al.. (2009). Phase III two by two factorial comparison of doxorubicin and cyclophosphamide followed by a taxan vs. a taxan alone, and paclitaxel vs. docetaxel in operable node positive breast cancer – results of the first interim analysis of NSASBC02 trial.. Cancer Research. 69(2_Supplement). 4103–4103. 2 indexed citations

18.

Mukai, Hirofumi, Toru Watanabe, Michihide Mitsumori, et al.. (2008). Safety and efficacy trial of preoperative sequential chemo-radiation therapy for the nonsurgical treatment (NST) in early breast cancer (EBC): Japan Clinical Oncology Group trial (JCOG0306). Journal of Clinical Oncology. 26(15_suppl). 601–601. 1 indexed citations

19.

Aogi, K., et al.. (2000). Telomerase activity in soft-tissue and bone sarcomas.. PubMed. 6(12). 4776–81. 33 indexed citations

20.

Aogi, K., et al.. (1993). [Intra-arterial infusion chemotherapy of cisplatin (CDDP)-lipiodol suspension using implantable injection port for unresectable liver cancer patients].. PubMed. 20(11). 1485–8. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact